This inventor holds 46 USPTO granted patents and 14 published patent applications, plus 3 CIPO patents and 31 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Novartis Ag. Active years: 2001-2025.
Location History:
- Edision, NJ (US) (2019)
- Boston, MA (US) (2022 - 2023)
- Edison, NJ (US) (2001 - 2024)
Company Filing History:
27 out of 2,405 
10 out of 4,770 
8 out of 3,973 
Years Active: 2001-2025
Areas of Expertise:
Title: The Innovative Contributions of Dong-Ming Shen
Introduction: Dong-Ming Shen, an accomplished inventor based in Edison, NJ, has made significant strides in the field of pharmaceutical sciences with a total of 45 patents to his name. His work primarily focuses on developing compounds and compositions aimed at treating conditions associated with NLRP activity, showcasing his dedication to improving healthcare outcomes through innovative research.
Latest Patents: Among his most recent patents, Shen has developed groundbreaking compounds of Formula AA and their pharmaceutically acceptable salts. These innovations are crucial for tackling medical conditions linked to NLRP activity. The compounds represent a leap forward in therapeutic options, potentially transforming the approaches taken in treatment protocols.
Career Highlights: Over the course of his career, Dong-Ming Shen has been associated with prestigious companies such as Merck Sharp & Dohme Corporation and Merck & Company, Inc. His time in these organizations has allowed him to refine his expertise and contribute to a plethora of advancements in medicinal chemistry. Shen's portfolio of 45 patents exemplifies his commitment to research and development within the pharmaceutical industry.
Collaborations: Throughout his career, Shen has collaborated with notable colleagues including Cheng Zhu and Shomir Ghosh. These partnerships have enriched his work, enabling him to leverage a diverse range of expertise and insights that have propelled his innovations further.
Conclusion: Dong-Ming Shen’s efforts in the realm of pharmaceutical innovation mark him as a key figure in the development of new treatment modalities. With a strong focus on compounds addressing NLRP activity, his contributions are not only impressive in number but also in their potential impact on healthcare. As he continues to advance in his career, Shen's commitment to innovation promises to yield further groundbreaking developments in the future.